Geneva, Aug. 29 -- International Clinical Trials Registry received information related to the study (NCT07129772) titled 'Perioperative Chemotherapy and Immunotherapy for Locally Recurrent Nasopharyngeal Carcinoma' on Aug. 11.
Study Type: Interventional
Study Design:
Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: The University of Hong Kong
Condition:
Nasopharyngeal Cancer Recurrent
Nasopharyngeal Cancinoma (NPC)
Intervention:
Drug: Gemcitabine (GEM)
Drug: Cisplatin
Recruitment Status: Not recruiting
Phase: Phase 2
Date of First Enrollment: November 1, 2025
Target Sample Size: 53
Countries of Recruitment:
Hong Kong
To know more, visit...